Opticyte
Opticyte is dedicated to transforming healthcare by developing innovative, real-time cellular oxygen monitoring technology to improve early detection and treatment of sepsis and organ failure, with a focus on health equity and accurate diagnostics across all skin tones.
Industries
Nr. of Employees
small (1-50)
Products
Noninvasive cellular O2 patient monitor (bedside/clinical monitor)
A bedside patient monitor that noninvasively measures and displays real-time oxygen levels inside cells using optical spectroscopy and algorithmic interpretation to aid early detection of organ dysfunction.
Noninvasive cellular O2 patient monitor (bedside/clinical monitor)
A bedside patient monitor that noninvasively measures and displays real-time oxygen levels inside cells using optical spectroscopy and algorithmic interpretation to aid early detection of organ dysfunction.
Services
Design and execution of hospital-based observational studies to evaluate cellular oxygenation measurements and their prognostic value in sepsis, trauma, and cardiac surgery.
Engineering and design collaboration with external partners to accelerate prototyping and product development for noninvasive cellular oximetry devices.
Design and execution of hospital-based observational studies to evaluate cellular oxygenation measurements and their prognostic value in sepsis, trauma, and cardiac surgery.
Engineering and design collaboration with external partners to accelerate prototyping and product development for noninvasive cellular oximetry devices.
Expertise Areas
- Clinical trial design and hospital-based observational studies
- Optical spectroscopy and noninvasive oximetry development
- Machine learning for biosignal analysis and fairness-aware model training
- Regulatory strategy and expedited FDA pathways
Key Technologies
- Optical spectroscopy for tissue and cellular oxygenation
- Noninvasive cellular oximetry
- Machine learning for biosignal interpretation
- Real-time continuous physiological monitoring
News & Updates
Opticyte was chosen as one of 61 startups for the highly competitive MedTech Innovator 2023 Cohort, gaining access to mentorship, industry partners, and funding opportunities.
The FDA recognized Opticyte’s Cell O2 Patient Monitor as a Breakthrough Device for its potential to reduce organ failure by providing real-time cellular oxygenation data.
Opticyte’s CEO Lori Arakaki participated in a panel discussion on creating successful academic spin-outs, sharing insights on innovation and commercialization.
Lori Arakaki discusses Opticyte’s commitment to addressing racial bias in pulse oximetry, especially highlighted during the COVID-19 pandemic.
Recognized by the FDA for its potential to provide more effective treatment for organ dysfunction, expediting regulatory review.
Opticyte was chosen as one of 61 startups for the highly competitive MedTech Innovator 2023 Cohort, gaining access to mentorship, industry partners, and funding opportunities.
The FDA recognized Opticyte’s Cell O2 Patient Monitor as a Breakthrough Device for its potential to reduce organ failure by providing real-time cellular oxygenation data.
Opticyte’s CEO Lori Arakaki participated in a panel discussion on creating successful academic spin-outs, sharing insights on innovation and commercialization.
Lori Arakaki discusses Opticyte’s commitment to addressing racial bias in pulse oximetry, especially highlighted during the COVID-19 pandemic.
Recognized by the FDA for its potential to provide more effective treatment for organ dysfunction, expediting regulatory review.